The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease
Open accessAbstract
BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year event-free survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). The 10-year overall survival estimates were 97% and 92%, respectively (P=0.001). In the H8-U trial, the estimated 5-year event-free survival rates were similar in the three treatment groups: 84% after six cycles of MOPP-ABV plus involved-field radiotherapy, 88% after four cycles of MOPP-ABV plus involved-field radiotherapy, and 87% after four cycles of MOPP-ABV plus subtotal nodal radiotherapy. The 10-year overall survival estimates were 88%, 85%, and 84%, respectively. CONCLUSIONS: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features. In patients with unfavorable features, four courses of chemotherapy plus involved-field radiotherapy should be the standard treatment. (ClinicalTrials.gov number, NCT00379041 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., Rosenberg, S. A., Coltman, C. A., & Tubiana, M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1630 · Cited by 1,639
Chronic Lung Disease after Premature Birth
Baraldi, E., & Filippone, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmra067279 · Cited by 1,070
Epidemiologic Analysis with a Programmable Calculator
Rothman, K. J., Boice, H. D., & Austin, H. D. (1982) · American Journal of Epidemiology · Cited by 1,039
Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia
Husain, A. N., Siddiqui, N. H., & Stocker, J. T. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90280-5 · Cited by 680
Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., Boissevain, F., de Wit, M., Mezger, J., Dühmke, E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.023 · Cited by 460
Ng, A. K., Bernardo, M. V. P., Weller, E., Backstrand, K., Silver, B., Marcus, K. C., Tarbell, N. J., Stevenson, M. A., Friedberg, J. W., & Mauch, P. M. (2002) · Blood · doi:10.1182/blood-2002-02-0634 · Cited by 433
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Bezjak, A., Wells, W. A., Burns, B. F., Winter, J. N., Horning, S. J., Dar, A. R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.085 · Cited by 323
Press, O. W., LeBlanc, M. L., Lichter, A. S., Grogan, T. M., Unger, J. M., Wasserman, T. H., Gaynor, E. R., Peterson, B. A., Miller, T. P., & Fisher, R. I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4238 · Cited by 147
Predictive Probability Early Termination Plans For Phase II Clinical Trials
Herson, J. (1979) · Biometrics · doi:10.2307/2530109 · Cited by 140
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Engert, A., Plütschow, A., Eich, H. T., Lohri, A., Dörken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K. C., Wilhelm, M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000067 · Cited by 928
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408648 · Cited by 762
André, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., van der Maazen, R., Re, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6394 · Cited by 542
Self-citationRecent Developments in Radiotherapy
Citrin, D. E. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608986 · Cited by 488
Metadata
- Authors
- Fermé, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., van't Veer, M. B., Walewski, J. A., Lederlin, P., Tirelli, U., Carde, P., Van Den Neste, E., Gyan, E., Monconduit, M., Diviné, M., Raemaekers, J. M. M., Salles, G., Noordijk, E. M., Creemers, G.-J., Gabarre, J., Hagenbeek, A., Reman, O., Blanc, M., Thomas, J., Vié, B., Kluin-Nelemans, J. C., Viseu, F., Baars, J. W., Poortmans, P., Lugtenburg, P. J., Carrie, C., Jaubert, J., & Henry-Amar, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-08
- Volume
- 357
- Issue
- 19
- Pages
- 1916-1927
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125790189
- Cited by
- 450
- References
- 9
- FWCI
- 19.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.